uniQure N.V. (QURE) - Stock Analysis
Last updated: Apr 4, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
uniQure’s Phase I/II Huntington’s gene therapy trial showed a 75% slowing of progression, triggering a 250% price surge and near five-year high. Strong FDA alignment for BLA filing and robust capital provide near-term growth catalysts despite technical overbought conditions and dilution risk.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Very high current ratio • Heavy non‑current debt • Negative free cash flow QURE has strong short-term liquidity and sizable investments supporting equity but faces high non‑current leverage and persistent operating cash burn leading to sustained losses and solvency risk.
Price Behavior
Key Price Behavior Insights: • Rapid recovery • Elevated volatility • Resistance cap Support Level: $9–$11; $14–$16 Resistance Level: $24–$28 QURE has shown a strong short‑term uptrend over the last month, rallying rapidly from the early‑March lows (~$9–$10) into the mid‑teens by 2026‑04‑02 but with elevated volatility and prior highs near $24–$28 posing key resistance.
Sentiment & News
Key News Insights: • Coordinated filings • FDA rebukes • Lead-plaintiff deadline Multiple plaintiff firms have launched coordinated securities class action notices against uniQure covering 2025-09-24–2025-10-31 amid FDA rebukes and allegations of distorted data, with an April 13, 2026 lead-plaintiff deadline.
AI Summary
UniQure is no longer a growth‑optional biotech but a tightly binary, event‑driven investment whose value will hinge on the outcome of a forced randomized AMT‑130 trial and near‑term readouts/regulatory accommodation for AMT‑260/AMT‑191, with litigation and a sizable non‑current debt burden amplifying downside if trials fail. Actionable: monitor trial design/endpoint agreements, cash burn vs. disclosed runway and debt maturities, and any non‑dilutive partnering or FDA minutes that would materially de‑risk the binary pathway.
Description
uniQure N.V. is a gene therapy company developing treatments for genetic and other severe diseases. Its lead program, etranacogene dezaparvovec (AMT-061), is in the Phase III HOPE-B trial for hemophilia B, and the broader pipeline includes clinical and preclinical candidates targeting central nervous system and neuromuscular disorders such as Huntington’s disease, Parkinson’s disease, temporal lobe epilepsy, ALS and forms of Alzheimer’s, as well as earlier-stage hemophilia approaches. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 29 | Oct 6 | QURE | uniQure N.V. | uniQure’s Phase I/II Huntington’s gene therapy trial showed a 75% slowing of progression, triggering a 250% price surge and near five-year high. Strong FDA alignment for BLA filing and robust capital provide near-term growth catalysts despite technical overbought conditions and dilution risk. | Closed | -10.9% |